AstraZeneca Pharma India has revealed its intention to sell its manufacturing facility in Bengaluru, as outlined in a regulatory filing. The company clarified that this decision is part of its ongoing strategic review and emphasized its commitment to prioritize the well-being of its employees.
In the filing, AstraZeneca Pharma India stated, “AstraZeneca Pharma India Limited (Company) remains committed to advance access to innovative medicines in India, with a clear ambition to be pioneers in science, lead in specialist disease areas, and transform patient outcomes. As a part of AstraZeneca’s ongoing strategic review of its Global Manufacturing and Supply Network, the Company intends to exit the manufacturing site in Bangalore, in due course.”
The company plans to position the manufacturing site for sale in a fully operational state and will initiate the search for a buyer capable of serving as a Contract Manufacturing Organisation (CMO) for the products currently produced or packaged at the Bengaluru site. It is important to note that these plans are subject to necessary statutory approvals.
Acknowledging the potential impact of this change, AstraZeneca emphasized its commitment to addressing the needs of its employees and ensuring an uninterrupted supply of medicines to patients. The company, established in 1979 with headquarters in Bengaluru, is a subsidiary of AstraZeneca Plc, UK. AstraZeneca India currently employs over 1,400 individuals nationwide, according to information available on their website.
AstraZeneca Pharma India focuses its efforts on the discovery, development, and commercialization of prescription medicines, particularly in the therapy areas of oncology, cardiovascular, renal, metabolism, and respiratory. The move to sell the Bengaluru manufacturing facility aligns with the company’s broader strategic goals and ongoing commitment to advancing healthcare in India.